)
Visual24 Oct 2025
The rise of Alphabet
Intellia Therapeutics (NTLA) investor relations material
Intellia Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Achieved or exceeded all operational and clinical objectives for H1 2025, with accelerated enrollment in all three Phase 3 studies and plans to expand the MAGNITUDE study to 1,200 patients.
Lead in vivo programs for ATTR amyloidosis and HAE are in Phase 3, progressing ahead of schedule, with strong clinical data showing a 98% reduction in HAE attacks and deep, durable TTR reduction in ATTR patients.
Strategic restructuring in January 2025 prioritized core programs, reduced workforce by 27%, and included real estate consolidation.
Expanded commercial and medical affairs leadership teams to support anticipated product launches and commercial readiness.
Announced planned retirement of Chief Medical Officer, with succession planning underway.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $630.5M as of 06/30/2025, down from $861.7M at 12/31/2024, reflecting $65M in non-recurring payments for restructuring and real estate.
Collaboration revenue rose to $14.2M in Q2 2025 from $6.9M in Q2 2024, mainly due to Regeneron cost reimbursements.
R&D expenses decreased to $97M in Q2 2025 from $114.2M in Q2 2024, driven by lower employee and stock-based compensation costs.
G&A expenses fell to $27.2M in Q2 2025 from $31.8M in Q2 2024, with lower stock-based compensation partially offset by commercial build-out costs.
Net loss narrowed to $101.3M in Q2 2025 from $147.0M in Q2 2024.
Outlook and guidance
Cash runway expected to fund operations into the first half of 2027 and through the anticipated first commercial launch.
MAGNITUDE trial enrollment to reach at least 650 patients by year-end 2025, with expansion to 1,200 pending regulatory review.
HAELO study randomization to complete in Q3 2025; BLA submission for lonvo-z planned for H2 2026.
Expenses projected to decrease in 2025 due to portfolio prioritization and restructuring.
Additional clinical data readouts for lonvo-z and nex-z expected in H2 2025.
Assess impact of MAGNITUDE expansion on timelines.
When is the BLA submission for lonvo-z expected?
Elaborate on commercial team buildout rationale.
What is the strategic rationale for ATTR-CM study expansion?
Lonvo-z: Payer reaction to one-time HAE therapy?
Nex-z: Impact of new RNAi on commercial positioning?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Intellia Therapeutics earnings date
Q3 20256 Nov, 2025
Next Intellia Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's therapies are based on a targeted genome editing platform, including CRISPR/Cas9 and proprietary next-generation programmable nucleases (PNs), which can induce a range of large deletions, substitutions or insertions across a target gene. The CRISPR/Cas9 genome editing technology has been shown to be effective in editing genomes in multiple cell types and organisms. Intellia Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage